RESPONDR ™ TNF EMPOWER
RESPONDR ™ TNF EMPOWER
-
Clinical Trial Information
Trial Contact: Tilme, Linda
Trial Phone: 321.843.5278
-
IRB No: 24.112.08
Protocol Abbrev: Respondr TNF test
Principal Investigator: Akash Pandey, MD
Age Group: Pediatric
-
Objective
1. Assess how health care providers (HCPs) integrate Respondr™ TNF into the clinical care
pathway for patients with inflammatory bowel disease (IBD) who may be considered for
biologic treatment, including anti-tumor necrosis factor antibodies (anti-TNF) such as
infliximab or adalimumab and their biosimilars (referred to collectively as IFX and ADA,
respectively).
2. Assess the impact of Respondr TNF test results on HCP’s clinical decision-making.
3. Evaluate patient outcomes at the first follow-up visit based on the patient’s standard of care
after incorporating Respondr TNF test results into treatment decisions.
4. Measure overall HCP satisfaction with the Respondr TNF test. -
Key Eligibility
The Respondr TNF test will be available to patients being considered for biologic therapy.
The test predicts an individual patient’s likelihood of responding to anti-TNF therapies prior
to treatment initiation. This information assists in therapy selection and patient management
decisions, ultimately improving the likelihood of a patient achieving remission and doing so
faster. The test considers intrinsic clearance and genetics to identify patients at an increased
risk of poor anti-TNF response, immunogenicity, and inadequate disease control to evaluate
likelihood to respond to anti-TNF therapies prior to treatment.
